Inhibitory effects of anti-rheumatic drugs on vascular endothelial growth factor in cultured rheumatoid synovial cells
Authors:
- 1 May 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 116 (2) , 360-365
Abstract
SUMMARY: Vascular endothelial growth factor (VEGF) is a potent inducer of angiogenesis and is constitutively expressed in the synovium of rheumatoid arthritis (RA). Over-expression of VEGF may play an important role in pathogenic vascularization and synovial hyperplasia of RA. In the present study, we examined whether disease-modifying anti-rheumatic drugs (DMARDs), including bucillamine (BUC), gold sodium thiomalate (GST), methotrexate (MTX) and salazosulfapiridine (SASP), act by inhibiting the production of VEGF by cultured synovial cells of patients with RA. Treatment of cultured synoviocytes with lipopolysaccharide (LPS) significantly increased VEGF production by cultured synovial cells. BUC significantly inhibited LPS-induced VEGF production, while GST tended to inhibit the production of VEGF. The inhibitory effects on VEGF production were dose-dependent. In contrast, MTX and SASP did not affect VEGF production. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis showed that BUC also inhibited LPS-induced VEGF mRNA expression in RA synovial cells. The present study provides the first evidence that BUC inhibits VEGF production and the expression of its mRNA in synovial cells of RA patients. Our results indicate that the anti-rheumatic effects of BUC are mediated by suppression of angiogenesis and synovial proliferation in the RA synovium through the inhibition of VEGF production by synovial cells.Keywords
This publication has 46 references indexed in Scilit:
- METHOTREXATE ACTION IN RHEUMATOID ARTHRITIS: STIMULATION OF CYTOKINE INHIBITOR AND INHIBITION OF CHEMOKINE PRODUCTION BY PERIPHERAL BLOOD MONONUCLEAR CELLSRheumatology, 1995
- Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndromeThe Lancet, 1994
- Regulation of B Cell Function by Bucillamine, a Novel Disease-Modifying Antirheumatic DrugClinical Immunology and Immunopathology, 1993
- Mechanism of Action of Methotrexate: Experimental Evidence that Methotrexate Blocks the Binding of Interleukin 1β to the Interleukin 1 Receptor on Target CellsClinical Chemistry and Laboratory Medicine (CCLM), 1993
- Differences in the effects of the antirheumatic drugs, bucillamine andd-penicillamine, on mitogen-induced proliferation of mouse spleen cellsInflammation Research, 1990
- Control of Oxidative Damage in Rheumatoid Arthritis By Gold(I)-Thiolate DrugsFree Radical Research Communications, 1990
- A study of pharmacokinetics and safety of salazosulfapyridine enteric coated tablet (PJ-306) in healthy Japanese subjects.Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics, 1990
- Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low‐dose methotrexateArthritis & Rheumatism, 1989
- Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cellsBiochemical and Biophysical Research Communications, 1989
- The pharmacokinetics of intramuscular gold sodium thiomalate in normal volunteersBiopharmaceutics & Drug Disposition, 1984